Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 18/20 | 0.71 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | CIT | O14578 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.43 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2499061 | 1.00 | HRH4 (0.71) | HRH4HTR3ACDC7CITCYP1A2 | |
| SCHEMBL2499056 | 1.00 | HRH4 (0.71) | HRH4HTR3ACDC7CITCYP1A2 | |
| SCHEMBL601784 | 0.83 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL601783 | 0.83 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL12193721 | 0.83 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL602906 | 0.82 | HRH4 (0.67) | HRH4HRH3 | |
| SCHEMBL602642 | 0.81 | HRH4 (0.65) | HRH4 | |
| SCHEMBL605976 | 0.80 | HRH4 (0.69) | HRH4HRH3 | |
| SCHEMBL12217534 | 0.80 | HRH4 (0.69) | HRH4HRH3 | |
| SCHEMBL12217517 | 0.79 | HRH4 (0.48) | HRH4CDC7HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040549-B1 | BENZOFURO-AND BENZOTHIENOPYRYIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-23 | — | — | EP | claimed |
| US-7576092-B2 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-18 | — | — | US | claimed |
| US-20080015200-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | claimed |
| US-8030321-B2 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2011-10-04 | — | — | US | disclosed |
| US-20090325927-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | CHAVEZ FRANK | 2009-12-31 | — | — | US | disclosed |
| US-7576092-B2 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-18 | — | — | US | disclosed |
| US-20080015200-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015200-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | HRH4, HRH1, HRH2 | HRH4 1/4885HTR3A 1070/4885CDC7 2574/4885 |
| US-20090325927-A1 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor | HRH4, HRH1, HRH2 | HRH4 1/4885HTR3A 1070/4885CDC7 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.